HUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376

SAN DIEGO: SAN DIEGO, Aug. 31, 2021 /PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, announced today the filing of an investigational new drug application (IND) with the FDA for HBI-2376 along with Genhouse who has filed an IND with the Chinese Center for Drug Excellence CDE. "HBI-2376 (GH21) is a SHP2 allosteric inhibitor with very high selectivity. Both in vitro and in vivo studies have shown that HBI-2376 is effective against multiple SHP2 point mutations and has a very good PK and safety profile," said Dr. Keifung Wang, CEO of Genhouse. "Therefore, GH21 is a very promising small molecule drug candidate that Genhouse along with HUYABIO will coordinate the global clinical development to make it available for cancer patients as soon as possible."
Click here to view original post